About Thermalin Inc.

Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).

Founded in 2010 based on pioneering work by Dr. Michael Weiss on the structure and function of insulin analogues, Thermalin is overcoming the limitations of existing insulin products by re-engineering the insulin molecule to be more stable and to act more quickly. Thermalin’s formulations of these new molecules enable new delivery devices and systems that will transform lives.

Our Patients

Managing diabetes demands conscientious compliance to closely control glucose levels. All people with Type 1 Diabetes and about a quarter of people with Type 2 diabetes must take daily injections or use an insulin infusion pump.  Unfortunately,  poorly performing insulin products constrain the capabilities of delivery systems and make compliance more difficult, leading to poor glycemic control and the long-term sequelae of under-treated diabetes, like blindness, dialysis, amputations, and cardiovascular disease.

Some of the challenges Thermalin is working to help people overcome:

Many people must inject insulin before a meal to mitigate the spike of blood sugar from digestion.

Today’s “rapid” insulins take 30-40 minutes to start acting (allowing blood sugar to spike at the beginning of the meal) and can keep acting for an hour or more after the meal has ended (causing blood sugar to fall too far after the meal). Like a captain steering a large boat within a narrow, winding channel, automated insulin pumps have difficulty dosing today’s too-slow insulins to keep blood sugar within the needed range.

The size and obtrusiveness of insulin pumps has long been an obstacle to their adoption.

Many patients prefer to inject themselves privately before meals rather than wear a visible stigma of their disease. Good treatment habits are frequently developed in childhood but too often are lost in the teenage years; for body-conscious teenagers, a pump that is too visible just won’t be used. This means many patients will not adopt the new, automated pumps that can significantly improve blood sugar control.

250,000 people in the U.S. and twice that number worldwide have Type 2 diabetes with extreme insulin resistance.

This syndrome has particularly high incidence among African Americans, Hispanic Americans, Native Americans, and people in Appalachia. Today’s rapid-acting insulins do not come in concentrated formulations. This means that to overcome their insulin resistance and control their blood sugar, these patients must inject large volumes of their meal-time and/or basal insulin.  Large injections are painful, which makes adherence (and good blood sugar control) very difficult for these individuals.

Diabetes is exploding in the developing world due to easier access to calories and less physically-demanding lifestyles.

Today’s insulins need to be refrigerated or they rapidly lose potency, forming amyloid “fibrils” that can also be immunogenic.  However, in many parts of the developing world patients do not have refrigerators and live long distances from clinics. Further, many of these clinics are not well served by “cold chain” distribution.  This means these patients do not have a reliable supply of needed insulin.

Our Science

Thermalin engineers therapeutic proteins to meet identified clinical needs based on a detailed structural understanding of the protein and its functional and dysfunctional interactions with itself and other molecules. Focused on these design objectives, we employ an extensive engineering toolkit to plan, simulate in-silico, then test in the lab new proteins that will have the desired clinical performance characteristics.

Some of the programs in our pipeline:

Type of Insulin

How It Will Lower Burden

Stage of Development

Stabilized & Ultra-Rapid

  • Pumps that are factory-filled, rather than filled by the patient
  • Better automated dosing by “closed loop” pumps

Stabilized, Ultra-Rapid, and Highly-Concentrated

  • 75% smaller insulin pumps
  • Smaller injections for people who need large doses

Our Team

The Thermalin Team includes scientists who have significantly influenced the world of insulin for over 30 years. Founder Michael Weiss has published over 150 peer reviewed articles (more than half on insulin) and VP of Development Bruce Frank is a co-inventor of Humalog, the first ever fast acting insulin.

Michael Weiss, M.D., PhD

Founder & Chief Invention Officer

Robert A. Harris Professor and Chairman of the Department of Biochemistry & Molecular Biology at Indiana University and Director of Chemical Biology and Biotherapeutics at the Indiana University Precision Health Initiative, Mike has more than 150 publications, including four on his insulin analogue designs that were named “Paper of the Week” by the Journal of Biological Chemistry. Mike just completed a 5-year term as chair of the NIDDK’s Board of Scientific Councilors.  Until December 2017, Dr. Weiss was Cowan-Blum Professor of Cancer Research and Professor of Biomedical Engineering, Biochemistry & Medicine (Endocrine) and Director of the Institute for Therapeutic Protein Engineering at Case Western Reserve University.  He earned a BA, summa cum laude in Physics in 1978, an MD, summa cum laude, in 1985, and a Ph.D. in biophysics in 1986, all from Harvard.

Edward Raskin, JD

Chief Executive Officer

Ed is a highly skilled and proven senior executive and board member in the life sciences including device and drug-device combination therapy, informed by sophisticated legal experience. As Co-Founder, Vice President and member of the Board of Directors of Beta Bionics, Ed was responsible for developing and aligning the company’s business goals and objectives with its public benefit structure, social mission and B Corp certification. In addition, he helped implement strategies for maximizing collaboration and relationships with strategic business partners and investors around the world. Previously, Ed was a founding partner in Kassinove & Raskin LLP, which defends and advises companies in the healthcare industry. Ed holds a JD from the UC Berkeley School of Law.

Dod Michael, PhD

Chief Scientific Officer and President

Prior to joining Thermalin, Dod’s 18-year career at Eli Lilly and Company culminated with his serving as the Senior Director responsible for insulin biology research.  Prior to Lilly, Dr. Michael was a post-doctoral fellow at the Joslin Diabetes Center/Harvard Medical School in Boston, MA in Dr. C. Ronald Kahn’s laboratory.  He received his Ph.D. from the University of Texas Southwestern Medical Center in Dallas in Cell and Molecular Biology and a B.S. from the University of Alabama.

Thomas Hattier, PhD

Vice President of R&D

Thom built Thermalin’s production and scientific teams in Cleveland. He is an accomplished researcher, who has driven development efforts in  the biotech and biopharma sectors, including at Myriad Genetics, AmpliCon, and Cellular Technology. Thom earned a BA at Connecticut College; an MS in biochemistry, PhD in pathology, and completed post-doctoral work in molecular genetics, all at Case Western Reserve University.

Bruce H. Frank, PhD

Senior Vice President of Insulin Discovery

Bruce was co-inventor of Humalog and retired from Eli Lilly after 34 years, where he held several senior management positions in insulin discovery, development, manufacturing, and regulatory affairs. He received his PhD in physical biochemistry from Northwestern University and did his post-doctoral work at Berkeley.

Bryan Keaney

Chief Financial Officer

Bryan brings extensive experience developing and managing the finance, administration and operations of life science companies.  He has overseen the growth of several healthcare related entities from formation through periods of rapid expansion into diversified, publicly traded operating companies.  Bryan’s professional experience includes serving as the CFO of Lincoln Peak Partners, Inc., VP of Finance of CombinatoRx, Inc., VP of Finance, Administration and Treasurer of Synta Pharmaceuticals Corp., CFO of Shionogi Bioresearch Corp. and held a variety of management roles at Interneuron Pharmaceuticals, Genzyme Corporation and Hybritech, Inc.  He has also provided consulting services to emerging technology-driven companies in multiple business sectors.  Bryan received a BS in Finance with honors from the Boston College School of Management.

Kraig Correll

Member of the Board

Kraig Correll is a highly accomplished banking professional with a Duke MBA. Kraig has over 10 years of Wall Street experience in private investment management in addition to over 15 years of marketing and sales experience in the pharmaceutical industry.

Veena Rao-Mirmira, PhD, MBA

Member of the Board

Veena Rao currently serves as Chief Commercial Officer of Beta Bionics and has over 20 years of experience in the diabetes space. Most recently, Veena led the external innovation team at Eli Lilly where she worked closely with the Lilly Diabetes team to establish key external relationships in automated insulin delivery, connected pens, glucose monitoring, and areas of digital health. Veena received an M.B.A. from the University of Virginia Darden School, an M.S. and a Ph.D., each in Chemical Engineering from Stanford University, and a B.S. in Chemical Engineering from the University of Minnesota

Tim Xiao

Member of the Board

Tim Xiao, CFA, FRM, is a Partner and founding team member at Delos Capital since its inception in 2014 and has over 13 years’ experience in investment banking and life sciences investment. Tim started his career as an investment banker at China International Capital and later joined the Investment Banking Division of Goldman Sachs where he completed a series of industry-defining transactions with a total deal value of over US$4 billion.

Tim serves as a Board member for Eccogene, Clover Biopharmaceuticals, OncoMyx Therapeutics, Curatia Medical, STRM.Bio, Thermalin and as a Board Observer for Allecra Therapeutics and Intrinsic Therapeutics. Tim was previously a Board member for Luqa Pharmaceuticals (acquired by China Medical System HKEx: 867).

Tim holds a Bachelor’s degree in International Business from Shanghai Jiao Tong University and is a CFA charterholder.

Important Developments…


Business Offices

Stoneham, MA 02180
[email protected]
(617) 938-3510

Thermalin FCOI Policy

Contact Us

Join Us

There are currently no openings at Thermalin.